Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Tuesday, July 20, 1999 Published at 10:40 GMT 11:40 UK


Health

Heart failure drug breakthrough

Almost 50% of heart failure victims die within five years

Adding a new drug into the cocktail used to treat heart failure cuts deaths by a third, according to research published on Monday.

The drug spironolactone, sold as Aldactone, is not currently approved for treating congestive heart failure which kills thousands in the UK every year.

But the significant study results have led to calls for it to be made standard treatment for the condition which stops the heart from pumping blood effectively.

Half of all patients die within five years of developing the condition, and overall 12% of those with heart failure will die in any one year.

The findings have such far-ranging implications for the treatment of the condition that the New England Journal of Medicine, which was planning to publish them in its September issue, has released the article early on its website.

Clinical tests on more than 1,600 patients proved so effective that they were stopped 18 months early.

Researchers said it would be unethical to carry on giving half the patients placebos and standard drug treatments.

Results showed that death rates were cut by 30% over two years and hospital admissions were down by 35%.

Diuretics

Aldactone, which costs just a few pence a day, was originally developed as a drug for treating water retention.

Standard treatment for heart failure is the use of other types of diuretic drug, and ACE inhibitors, which control high blood pressure.

Some doctors add beta-blockers, another class of drugs which can reduce high blood pressures, to the mixture.

Dr Pitt is recommending adding Aldactone as a fourth drug to the cocktail.

In the trials, some 386, or 46% of the patients who did not receive Aldactone died within five years.

This compared with 284, or 35% of the patients who died after being given the Aldactone cocktail.

"The decrease in cardiac death and hospitalisation was dramatic," said Dr Bertram Pitt, of the University of Michigan School of Medicine, who led the research.

The British Heart Foundation said today in a statement that the study was "potentially very exciting".

"Although the British Heart Foundation has not yet had the opportunity to study the trial results in detail, it would appear that this could be a very important way for doctors to help their heart failure patients.

"Clearly, it is important that the research results are subject to proper scrutiny before patients should expect to have access to this drug. But if the effects of this treatment are as great as suggested by this study, the potential benefit in terms of lives saved could be huge."



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

09 Jun 99 | Health
Heart patients miss out on aftercare

27 Apr 99 | Health
Cabernet 'best for the heart'

24 Mar 99 | Health
Heart patients'dying unnecessarily'





Internet Links


British Heart Foundation

The heart online


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99